Prognostic value of serum progranulin in de novo adult acute myeloid leukemia patients
Background: Elevated serum progranulin (PGRN) levels have been associated with a wide range of different human malignancies. However, data available on the role of PGRN in hematological malignancies are limited. Methods: Measurement of the PGRN level in serum of adult de novo acute myeloid leukemia...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137921000559 |
| _version_ | 1811172227551330304 |
|---|---|
| author | Mohamed O. Azazzi Amro M.S. El-Ghammaz Haydi S. Mohamed |
| author_facet | Mohamed O. Azazzi Amro M.S. El-Ghammaz Haydi S. Mohamed |
| author_sort | Mohamed O. Azazzi |
| collection | DOAJ |
| description | Background: Elevated serum progranulin (PGRN) levels have been associated with a wide range of different human malignancies. However, data available on the role of PGRN in hematological malignancies are limited. Methods: Measurement of the PGRN level in serum of adult de novo acute myeloid leukemia (AML) patients using enzyme-linked immunosorbent assay (ELISA) was performed. Results: The mean serum PGRN level in AML patients was higher than that in controls (346.08 pg/ml ± 64.46 vs 155 pg/ml ± 63 respectively; p = 0.001). After a mean duration of follow-up equaling 140 days, patients with high serum PGRN (i.e., higher than 370.5 pg/ml) had inferior overall survival (OS) in comparison to patients with low serum PGRN (i.e., lower than 370.5 pg/ml) (OS = 25% vs 60.7%, mean survival = 107 days vs 256.5 days, p = 0.007). On the other hand, remitted patients on day 28 with high serum PGRN (i.e., higher than 307.5 pg/ml) did not differ from those with low serum PGRN (i.e., lower than 307.5 pg/ml) regarding disease-free survival (DFS) (DFS = 78.6% vs. 87.5%, mean survival = 301.3 days vs. 283.5 days, p = 0.789). Moreover, the serum PGRN level was associated with inferior OS (p = 0.024) on multivariate analysis. Conclusion: Adult de novo AML patients have elevated serum PGRN levels and a high PGRN level is associated with an inferior OS. |
| first_indexed | 2024-04-10T17:26:19Z |
| format | Article |
| id | doaj.art-c329b5796803489294e399dbf97e2457 |
| institution | Directory Open Access Journal |
| issn | 2531-1379 |
| language | English |
| last_indexed | 2024-04-10T17:26:19Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj.art-c329b5796803489294e399dbf97e24572023-02-04T04:18:23ZengElsevierHematology, Transfusion and Cell Therapy2531-13792023-01-014512531Prognostic value of serum progranulin in de novo adult acute myeloid leukemia patientsMohamed O. Azazzi0Amro M.S. El-Ghammaz1Haydi S. Mohamed2Faculty of Medicine, Ain Shams University, EgyptFaculty of Medicine, Ain Shams University, Egypt; Faculty of Medicine in Rabigh, King Abdulaziz University, Kingdom of Saudi ArabiaFaculty of Medicine, Ain Shams University, Egypt; Corresponding author at: Lecturer of Internal Medicine, Clinical Hematology and Bone Marrow Transplantation, Faculty of Medicine, Ain Shams University, Egypt.Background: Elevated serum progranulin (PGRN) levels have been associated with a wide range of different human malignancies. However, data available on the role of PGRN in hematological malignancies are limited. Methods: Measurement of the PGRN level in serum of adult de novo acute myeloid leukemia (AML) patients using enzyme-linked immunosorbent assay (ELISA) was performed. Results: The mean serum PGRN level in AML patients was higher than that in controls (346.08 pg/ml ± 64.46 vs 155 pg/ml ± 63 respectively; p = 0.001). After a mean duration of follow-up equaling 140 days, patients with high serum PGRN (i.e., higher than 370.5 pg/ml) had inferior overall survival (OS) in comparison to patients with low serum PGRN (i.e., lower than 370.5 pg/ml) (OS = 25% vs 60.7%, mean survival = 107 days vs 256.5 days, p = 0.007). On the other hand, remitted patients on day 28 with high serum PGRN (i.e., higher than 307.5 pg/ml) did not differ from those with low serum PGRN (i.e., lower than 307.5 pg/ml) regarding disease-free survival (DFS) (DFS = 78.6% vs. 87.5%, mean survival = 301.3 days vs. 283.5 days, p = 0.789). Moreover, the serum PGRN level was associated with inferior OS (p = 0.024) on multivariate analysis. Conclusion: Adult de novo AML patients have elevated serum PGRN levels and a high PGRN level is associated with an inferior OS.http://www.sciencedirect.com/science/article/pii/S2531137921000559Acute myeloid leukemiaSerum progranulin levelOutcome |
| spellingShingle | Mohamed O. Azazzi Amro M.S. El-Ghammaz Haydi S. Mohamed Prognostic value of serum progranulin in de novo adult acute myeloid leukemia patients Hematology, Transfusion and Cell Therapy Acute myeloid leukemia Serum progranulin level Outcome |
| title | Prognostic value of serum progranulin in de novo adult acute myeloid leukemia patients |
| title_full | Prognostic value of serum progranulin in de novo adult acute myeloid leukemia patients |
| title_fullStr | Prognostic value of serum progranulin in de novo adult acute myeloid leukemia patients |
| title_full_unstemmed | Prognostic value of serum progranulin in de novo adult acute myeloid leukemia patients |
| title_short | Prognostic value of serum progranulin in de novo adult acute myeloid leukemia patients |
| title_sort | prognostic value of serum progranulin in de novo adult acute myeloid leukemia patients |
| topic | Acute myeloid leukemia Serum progranulin level Outcome |
| url | http://www.sciencedirect.com/science/article/pii/S2531137921000559 |
| work_keys_str_mv | AT mohamedoazazzi prognosticvalueofserumprogranulinindenovoadultacutemyeloidleukemiapatients AT amromselghammaz prognosticvalueofserumprogranulinindenovoadultacutemyeloidleukemiapatients AT haydismohamed prognosticvalueofserumprogranulinindenovoadultacutemyeloidleukemiapatients |